COMPANY

Kubota Vision

Profile checked Oct 10, 2026

Keywords: Myopia Geographic Atrophy Stargardt Disease Macular Edema Macular Degeneration Age Related Macular Degeneration Keratoconjunctivitis Sicca Progressive Myopia Vision Disorders Proliferative Diabetic Retinopathy Macular Atrophy Dry Eye Syndrome Primary Open-angle Glaucoma Ocular Hypertension Dry Age-related Macular Degeneration Dry Eye Syndromes Dry Eye ACU-4429 Rebamipide Emixustat RHMS-RTM Kubota Glass OPA-6566

21Trials (company is sponsor)

Timeline

Jul 6, 2026 Trial start Not phased (device or behavioral study): A Controlled Evaluation of Optical Defocus Parameters on Transient Changes in Axial Length Using Kubota Glass source ↗
Nov 1, 2023 Trial start Not phased (device or behavioral study): Kubota Glass Parameter Refinement Study source ↗
Oct 1, 2023 Trial start Not phased (device or behavioral study): Electronic Spectacles Versus Low Dose Atropine in Young Myopes source ↗
Jun 23, 2022 Trial start Not phased (device or behavioral study): Binocular Peripheral Myopic Defocus Using a Clinical Prototype Device source ↗
Nov 11, 2020 Trial start —: Evaluation of the Retinal Health Monitoring System Thickness Module source ↗
Jun 29, 2020 Trial start Not phased (device or behavioral study): Projected Peripheral Defocus Using a Wearable Device source ↗
Apr 11, 2020 Trial start Not phased (device or behavioral study): Effects of Projected Peripheral Defocus on Ocular Biometrics source ↗
2020-04 Trial start —: Study Evaluating Retinal Health Monitoring System Thickness Module source ↗
Nov 20, 2019 Trial start —: Study Evaluating Retinal Health Monitoring System Visual Acuity Module. source ↗
Jan 7, 2019 Trial start Phase 3: Safety and Efficacy of Emixustat in Stargardt Disease source ↗
2017-01 Trial start Phase 2: Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease source ↗
2016-05 Trial start Phase 2: Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy source ↗
2014-04 Trial start Phase 1: Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration source ↗
2013-02 Trial start Phase 2/Phase 3: Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride source ↗
2012-06 Trial start Phase 3: Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome source ↗
2011-09 Trial start Phase 1/Phase 2: Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension source ↗
2010-02 Trial start Phase 2: Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea source ↗
2009-12 Trial start Phase 2: Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye source ↗
2009-10 Trial start Phase 2: Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy source ↗
2009-07 Trial start Phase 1: Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects source ↗
2008-05 Trial start Phase 1: Safety and Tolerability of ACU-4429 source ↗

Upcoming milestones

Dec 1, 2026 (ESTIMATED) · Not phased · A Controlled Evaluation of Optical Defocus Parameters on Transient Changes in Axial Length Using Kubota Glass · NCT07686289

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 21

Record	Title	Phase	Status	Start	Primary completion
NCT07686289	A Controlled Evaluation of Optical Defocus Parameters on Transient Changes in Axial Length Using Kubota Glass	Not phased (device or behavioral study)	Not yet recruiting	Jul 6, 2026	Dec 1, 2026 (estimated)
NCT06085430	Kubota Glass Parameter Refinement Study	Not phased (device or behavioral study)	Completed	Nov 1, 2023	Sep 30, 2024 (actual)
NCT06034379	Electronic Spectacles Versus Low Dose Atropine in Young Myopes	Not phased (device or behavioral study)	Recruiting	Oct 1, 2023	2025-12 (estimated)
NCT03772665	Safety and Efficacy of Emixustat in Stargardt Disease	Phase 3	Completed	Jan 7, 2019	Jun 13, 2022 (actual)
NCT05425108	Binocular Peripheral Myopic Defocus Using a Clinical Prototype Device	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	Jun 23, 2022	2023-08 (estimated)
NCT04415684	Projected Peripheral Defocus Using a Wearable Device	Not phased (device or behavioral study)	Completed	Jun 29, 2020	Aug 20, 2020 (actual)
NCT04388020	Effects of Projected Peripheral Defocus on Ocular Biometrics	Not phased (device or behavioral study)	Completed	Apr 11, 2020	May 14, 2020 (actual)
NCT02753400	Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy	Phase 2	Completed	2016-05	2017-11 (actual)
NCT03033108	Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease	Phase 2	Completed	2017-01	2017-11 (actual)
NCT04428242	Study Evaluating Retinal Health Monitoring System Thickness Module	Not listed	Withdrawn	2020-04	2020-06 (estimated)
NCT04169802	Study Evaluating Retinal Health Monitoring System Visual Acuity Module.	Not listed	Completed	Nov 20, 2019	Apr 15, 2020 (actual)
NCT04499703	Evaluation of the Retinal Health Monitoring System Thickness Module	Not listed	Completed	Nov 11, 2020	Jan 25, 2021 (actual)
NCT01802866	Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride	Phase 2/Phase 3	Completed	2013-02	2016-04 (actual)
NCT02130531	Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration	Phase 1	Completed	2014-04	2015-09 (actual)
NCT01632137	Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome	Phase 3	Completed	2012-06	2013-06 (actual)
NCT01410188	Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension	Phase 1/Phase 2	Completed	2011-09	2012-10 (actual)
NCT01002950	Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy	Phase 2	Completed	2009-10	2012-06 (actual)
NCT00703183	Safety and Tolerability of ACU-4429	Phase 1	Completed	2008-05	2009-06 (actual)
NCT01027013	Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye	Phase 2	Completed	2009-12	2010-10 (actual)
NCT01057147	Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea	Phase 2	Completed	2010-02	2011-01 (actual)
NCT00942240	Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects	Phase 1	Completed	2009-07	2010-04 (actual)